This inventor holds 3 USPTO granted patents. Top assignees: Hsc Research and Development Limited Partnership, Telios Pharmaceuticals, Inc.. Active years: 1998-2000.
Company Filing History:
2 out of 36 
1 out of 1 Years Active: 1998-2000
Title: Carmelo Bernabeu: Innovator in TGF-β-Binding Glycoproteins
Introduction
Carmelo Bernabeu is a notable inventor based in Madrid, Spain. He has made significant contributions to the field of biotechnology, particularly in the area of TGF-β-binding glycoproteins. With a total of 3 patents to his name, Bernabeu's work has the potential to impact therapeutic approaches in medicine.
Latest Patents
One of his latest patents is focused on the recombinant production of soluble TGF-β-binding endoglin. This invention provides a novel purified TGF-β-binding glycoprotein, endoglin, along with an isolated nucleic acid molecule that encodes an amino acid sequence corresponding to this glycoprotein. The patent also includes a pharmaceutical composition that comprises the endoglin-derived polypeptide purified by Bernabeu or produced by his recombinant methods, along with a pharmaceutically acceptable carrier. Methods of treating patients using this pharmaceutical composition are also outlined in the patent.
Another significant patent by Bernabeu involves soluble TGF-β-binding endoglin polypeptides and homodimers. Similar to his previous invention, this patent provides a purified TGF-β-binding glycoprotein, endoglin, and details the isolated nucleic acid molecule encoding the corresponding amino acid sequence. The pharmaceutical composition and treatment methods are also included, showcasing Bernabeu's innovative approach to biotechnology.
Career Highlights
Carmelo Bernabeu has worked with various organizations throughout his career. Notably, he has been associated with HSC Research and Development Limited Partnership and Telios Pharmaceuticals, Inc. His work in these companies has contributed to advancements in the field of biotechnology and pharmaceuticals.
Collaborations
Throughout his career, Bernabeu has collaborated with esteemed colleagues, including Michelle Letarte and Joan Massague. These collaborations have likely enriched his research and contributed to his innovative patents.
Conclusion
Carmelo Bernabeu is a prominent inventor whose work in TGF-β-binding glycoproteins has the potential to advance medical treatments. His patents reflect a commitment to innovation in biotechnology, and his collaborations further enhance the impact of his contributions.